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The outcome of lymphoma has definitely improved over the last few decades which is
mainly due to the introduction and development of novel and effective therapeutic
approaches. Nevertheless, a small though notable group of patients may display a poor
response to treatments, with a true refractoriness or a transient response followed by
early relapse. The present review addresses the issue of refractory disease among
patients with lymphoma, focusing on the overall incidence and the main clinical aspects
associated with refractoriness. Rev. Bras. Hematol. Hemoter. 2009;31(Supl. 2):15-18.
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Introduction
Hodgkin's (HL) and non-Hodgkin's (NHL) lymphomas
are malignant tumors usually characterized by a high
response-rate to chemo-radiotherapy. Among NHL, peculiar
epidemiology features have been observed, with the incidence
progressively increasing over the last 50 years up to the
value of 19.5 per 100,000 individuals per year, based on cases
diagnosed in 2002-2006. Indeed, the incidence of NHL has
increased 0.6% per year during the period 1991-2004, while
mortality clearly shows a decrease of 3.2% per year. For HL,
the incidence has been decreasing slightly over the last 30
years, dropping to the value of 2.8 per 100,000 individuals
per year (2002-2006 diagnoses). Again, the mortality rate of
HL has shown a marked reduction, with trend rates analogous
to those observed in NHL. At present, the overall age-adjusted
mortality rate of NHL is 7.1 per 100,000/year and 0.4 per
100,000/year for HL according to the most recent survey by
SEER.1 Thus, the outcome of lymphoma has definitely
improved over the last few decades which is mainly due to
the introduction and development of novel and effective
therapeutic approaches.
In the field of lymphoma, several treatment options have
been successfully employed, including high dose
chemotherapy, autologous stem cell transplantation and
different classes of new biological drugs, in particular the
chimerical and humanized monoclonal antibodies directed
against lymphocyte-specific antigens. Progressively, a great
fraction of patients can now obtain complete response, which
is often durable. This results in prolonged survival which
frequently means the cure of an otherwise fatal malignant
disease. Nevertheless, a small though notable group of
patients may display a poor response to treatment, with true
refractoriness or a transient response followed by early
relapse. Appropriate studies are needed to identify possible
early predictors of refractory disease. This will allow the
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investigation of novel therapeutic programs suitable for
patients at high risk of poor response to standard treatment
approaches.
The present review addresses the issue of refractory
disease among patients with lymphoma, focusing on the
overall incidence and the main clinical aspects associated
with refractoriness.
Refractory disease in high-risk follicular
lymphoma
To evaluate the efficacy of high-dose therapy and ASCT
in the treatment of Follicular Lymphoma (FL) a randomized
multicenter trial comparing intensive therapy vs. conventional
chemotherapy, both supplemented with Rituximab, has
recently been performed in high-risk FL at diagnosis. Most
Italian Centers associated to GITMO (Gruppo Italiano
Trapianto Midollo Osseo) and to IIL (Intergruppo Italiano
Linfomi) participated to the study. The intensive arm was the
high-dose sequential (HDS) schedule, developed several
years ago for FL and other indolent lymphoma2 while the
conventional arm was the well known CHOP (cyclo-
phosphamide/doxorubicin/vincristine/prednisone) scheme.
Four to six doses were included in the HDS scheme (R-HDS)
and at completion of 6 CHOP courses (CHOP-R). Overall, 136
patients were enrolled and evaluable for response to
treatment. Preliminary results have been recently reported in
Blood.3 In summary, R-HDS proved to have a more potent
anti-lymphoma activity compared to CHOP-R, with 4-year
EFS of 61% and 28%, respectively (P < .001), at a median
follow-up (MFU) of 51 months. However, this did not
translate in survival advantages. Indeed, no difference in
overall survival (OS) was observed between patients of the
two treatment arms. Interestingly, molecular remission (MR)
was achieved in 44% of CHOP-R and 80% of R-HDS patients
(P < .001), and was the strongest independent outcome
predictor.
The presence of refractory patients was clearly
documented in this randomized study. As shown in Table 1,
complete remission (CR) was 62% with CHOP-R and 85%
with R-HDS (P < .001). The difference in the rate of CR was
mainly due to the different proportion of non-responding,
i.e. refractory, patients. In fact, approximately 30% of patients
receiving CHOP-R had a poor response, displaying
progressive or stable disease; poor responders were
approximately 10% in the R-HDS arm. Thus, in spite of the
effective treatment delivered (CHOP or HDS both
supplemented with rituximab) there is still a variable, non-
negligible, group of patients displaying refractory disease.
The cross-over design of the study offered a good
opportunity of rescue to patients failing after CHOP-R. Indeed,
patients refractory or early-relapsing after CHOP-R underwent
salvage with R-HDS. As shown in Table 2, salvage R-HDS
had an 80% CR rate and a 68% 3-year EFS (MFU, 30 months).
Thus, most patients with poor response to CHOP-R
experienced a prolonged survival following R-HDS as rescue
and this explains the lack of difference in OS between the two
treatment arms. In conclusion, the study offered several
important insights for the management of high-risk FL. In
particular, it has been confirmed that achieving CR and MR is
critical for effective disease control, regardless of which
treatment is used; overall, R-HDS given front-line ensures
superior disease control and molecular outcome than CHOP-
R, but no improvement in OS; lastly, the presence of FL
patients with refractory disease is a major concern, particularly
with conventional chemo-immunotherapy such as CHOP-R;
however, primary failures after CHOP-R have a good outcome
if rescued with R-HDS. Taken together, all these aspects
suggest that relapsed/refractory FL might be the most
appropriate setting for R-HDS-like treatments.
Incidence of refractory disease in NHL other than
follicular subtype
To increase cure rates in patients with aggressive or
refractory/relapsing NHL, intensive treatments and ASCT
have been extensively investigated, mostly in patients
younger than 60 to 65 years.4.5 Applicability and efficacy of
the HDS approach has been improved by the use of mobilized
peripheral blood cells (PBSC) for the autograft procedure.6,7
Moreover, the use of agents such as the monoclonal anti-
CD20 antibody and rituximab (R), has markedly improved the
therapeutic efficacy of ASCT-based programs by the in vivo
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purging effect on PBSC harvests, as reported by other groups
and by a recent study from our cooperative GITIL (Gruppo
Italiano Terapie Innovative nei Linfomi) group.8-12
In the setting of Diffuse Large B-cell lymphoma (DLB-
CL), the GITIL group has recently completed a prospective
multicenter study evaluating the rituximab-supplemented,
early-intensified high-dose chemotherapy regimen, delivered
with multiple autologous support using in-vivo purged PBPC,
in a series of 112 previously untreated patients with DLB-CL
and aaIPI 2 or 3. Both response and long-term outcome were
definitely promising, and compare quite favorably with the
dismal outcome commonly observed in poor-risk DLB-CL
treated with conventional chemotherapy regimens.13 Overall
90 patients (80.4%) reached CR. However, again the major
cause of treatment failure was disease progression,
documented in 12 (11%) patients. This is consistent with the
selection of a true poor-risk patient population, with some
cases displaying a highly refractory disease, unresponsive
to repeated courses of high-dose cytotoxic drugs given at
short intervals. Moreover, the result confirms that a variable
proportion of NHL patients may be primary refractory, even
to high-dose therapy with rituximab.
In order to assess the real number of NHL patients with
refractory or early-relapsing disease, a recent study was
undertaken to evaluate the actual rate of refractory patients.
The long-term outcome of primary refractory vs. responsive
patients is also under evaluation. Data have been collected
on a series of 503 NHL patients referred and treated at our
institutions between 1995 and 2005. The group included 461
B-cell and 42 T-cell NHL; main histological subtypes consisted
of: 305 high-grade NHL, 183 low-grade NHL and 15 mantle-
cell lymphoma. Overall, 126 (25%) patients were refractory
(39% with no response at all and 61% with short-lasting
response soon followed by disease progression). The rate of
refractoriness was as high as 40% in the small T-cell NHL
subgroup, while the overall incidence was 24% for B-cell
NHL. There was no significant difference in the distribution
of refractory patients among the histological subtypes of B-
NHL, in other words none of the B-cell NHL subtypes was
specifically associated with poorer response to treatment.
The use of the HDS program as front-line treatment was
significantly associated with reduced risk of refractory disease
(OR=0.30). These data apparently suggest that better outcome
could derive by an early use of the HDS approach in newly
diagnosed NHL with advanced stage of disease and other
typical clinical features of poor prognosis.14 Indeed, further
studies are still needed, in order to identify patients unfit to
receive conventional treatment due to poorly responsive
disease as early as possible. For these patients, the prompt
institution of alternative treatment approaches might increase
the chances of achieving disease remission.
At present, therapeutic procedures available for the
rescue of patients displaying overt refractory disease
apparently do not improve the chance of long-term survival.
Life expectancy remains dramatically poor for patients with
refractory or early relapsing disease. Indeed, in our analysis
it was possible to observe that refractory patients had a
definitely short life expectancy, with a median survival of 21
months and a 14-year survival projection of 10%, which is
markedly worse compared to the 88%, 76% and 65% survival
projections at 5, 10 and 15 years, respectively, of responsive
patients. Several studies have shown some efficacy of ASCT
in the salvage treatment of NHL.4, 5,15 In addition, allogeneic
stem cell transplantation is an effective treatment option which
seems to improve the outcome of refractory patients,
particularly since the development of the reduced intensity
conditioning regimen (RIC).16
Conclusion
The results herein presented indicate that a non-
negligible proportion of NHL patients have refractory disease.
Overall, refractory patients represent approximately one
quarter of NHL cases undergoing induction therapy. Besides
advanced stage and high LDH levels, no other clinical and
histological factors are specifically associated to
refractoriness; indeed, further studies are needed to identify
possible molecular markers predictive of refractoriness in order
to design induction therapies adapted for refractory patients
given their dismal outcome with currently available treatment
strategies. A lot of new small molecules that target bcl-2, bcl-
6, mTOR, the AKT pathway (deforolimus), P-glycoprotein
(Zosuquidar), histone deacetylase (SAHA) and NF-kB have
shown promising activity in preclinical and early-phase clinical
studies.17,18 Moreover, a clear benefit has been documented
with some new drugs or combination of drugs, including
lenalidomide, bendamustine and the radiolabeled anti-CD20
Zevalin.19,20,21 New targets and new drugs should be carefully
considered as an important tool in the effort to improve the
very poor outcome of patients with refractory lymphoma.
Resumo
A evolução dos linfomas tem sido definitivamente melhorada ao
longo das últimas décadas. Isto se deve principalmente devido à
introdução e desenvolvimento de novas e efetivas abordagens
terapêuticas. Apesar disto, uma pequena parcela deste notável
grupo de pacientes pode apresentar uma pobre resposta aos
tratamentos, com uma verdadeira refratariedade, ou com resposta
transitória e precocemente uma recidiva. A presente revisão aborda
este assunto da doença refratária nos pacientes com linfoma,
enfocando sua incidência global e os principais aspectos clínicos
associados à refratariedade. Rev. Bras. Hematol. Hemoter. 2009;
31(Supl. 2):15-18.
Palavras-chave: Linfoma de Hodgkin; linfomas não Hodgkin;
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refratária.
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